Introduction
The intersection of the HIV epidemic and the burden of cervical cancer represents a significant challenge for global health. Women living with HIV (WLWH) face a disproportionately high risk of developing cervical cancer, often presenting at younger ages and experiencing more aggressive disease courses compared to their HIV-negative counterparts. This disparity is driven by the synergistic relationship between HIV-induced immunosuppression and persistent infection with high-risk human papillomavirus (HPV) genotypes. To address these challenges, clinical guidelines must be rooted in robust, age-specific data that balance the benefits of early detection with the risks of over-medicalization. A seminal study published in Lancet HIV provides a comprehensive individual patient data meta-analysis (IPDMA) that clarifies the optimal timing and frequency for cervical screening and treatment follow-up in this high-risk population.
Highlights
Key takeaways from the research include:
The risk of high-grade cervical intraepithelial neoplasia (CIN2/3) among women living with HIV increases significantly with age, reaching a peak probability of 58.1% in the 45–49-year age group. Invasive cervical cancer remains rare in women living with HIV before the age of 30, providing a scientific basis for initiating screening at age 25 rather than earlier. Women living with HIV who test negative on both cytology and HPV testing maintain a low risk of progression for approximately 3 to 5 years, supporting extended screening intervals for double-negative cohorts. Post-treatment recurrence of CIN2+ is alarmingly high among women living with HIV, with rates reaching 57% at 10 years, necessitating rigorous long-term surveillance.
Background and Disease Burden
Cervical cancer is a preventable disease, yet it remains a leading cause of mortality among women in low- and middle-income countries (LMICs), where the prevalence of HIV is often high. WLWH are approximately six times more likely to develop cervical cancer than women without HIV. This elevated risk is attributed to several factors: a higher prevalence of persistent HPV infections, a broader range of high-risk HPV genotypes, and a diminished ability of the immune system to clear precancerous lesions. Despite the widespread rollout of antiretroviral therapy (ART), which has significantly extended the lifespan of WLWH, the risk of cervical malignancy remains substantially higher than in the general population. This study was initiated to provide the World Health Organization (WHO) with the evidentiary framework needed to update screening and treatment recommendations specifically for WLWH.
Study Design and Methodology
The researchers conducted a dual-phase investigation consisting of a systematic literature review and an individual patient data meta-analysis (IPDMA). The systematic review encompassed databases including MEDLINE, Embase, and the Cochrane Library for the period between January 2012 and October 2019, building upon a previous review that covered data up to 2012. The inclusion criteria focused on studies reporting histopathologically confirmed cervical precancer (CIN2+) and cancer outcomes in WLWH across various age groups. For the IPDMA, the authors collaborated with researchers from 55 potentially eligible studies, ultimately securing data from eight studies across seven countries: Burkina Faso, Cameroon, India, Kenya, South Africa, Thailand, and the USA. This combined dataset included 72,350 women, of whom 12,527 were living with HIV. The primary outcomes were the age-specific probabilities of CIN2, CIN3, and invasive cervical cancer. Random-effects models were employed to calculate predicted probabilities while adjusting for HIV status and ART use.
Key Findings and Statistical Analysis
The IPDMA provided a detailed map of how cervical disease progresses in women living with HIV across the lifespan. The results underscored a clear, age-dependent escalation in risk. For the youngest cohort (ages 15–19), the predicted probability of CIN2 or CIN3 was 6.0% (95% CI: 0.74–64.1). This probability rose sharply to 32.4% (95% CI: 8.3–72.7) in the 20–24 age group and continued to climb through the 30s and 40s. The highest risk was observed in women aged 45–49 years, with a pooled predicted probability of 58.1% (95% CI: 17.0–81.5). Interestingly, invasive cervical cancer (ICC) was found to be exceedingly rare in WLWH under the age of 30. This finding is critical, as it suggests that while precancerous lesions are common in the early 20s, the progression to invasive disease typically takes a decade or more, allowing for a window of intervention starting at age 25. Regarding screening intervals, the systematic review found that WLWH who achieved a negative result on both baseline cytology and HPV testing had a low cumulative incidence of developing CIN2+ (0.8% to 5%) over a period of 4 to 6 years. However, for those with only a negative cytology result, the risk of developing any grade of CIN within 12 years was as high as 10%. Furthermore, the data on post-treatment outcomes were sobering. Even after successful treatment for CIN2+, WLWH experienced high recurrence rates: 11–27% within one year and up to 57% by the ten-year mark. This suggests that the immune environment in WLWH facilitates the persistence or reinfection of HPV even after local excision or ablation of lesions.
Expert Commentary and Clinical Implications
The findings of this study have profound implications for clinical practice and public health policy. The low incidence of invasive cancer before age 30 supports the WHO’s decision to move the screening initiation age for WLWH to 25. This allows healthcare systems to focus resources where they are most likely to prevent mortality while avoiding the potential harms of over-treating transient HPV infections in very young women. However, the data also highlight a critical gap in care: the management of women post-treatment. The high recurrence rates suggest that a single treatment is often insufficient for long-term protection in WLWH. Clinicians must maintain high vigilance and implement standardized, frequent follow-up protocols for this population. Additionally, while the study emphasizes the importance of screening, it also reinforces the need for primary prevention through HPV vaccination. For WLWH who were not vaccinated as adolescents, the high probability of CIN2/3 by age 25 highlights the urgency of screening and the potential benefit of catch-up vaccination, although the latter’s efficacy in older WLWH is still a subject of ongoing research. The geographical diversity of the data—spanning Africa, Asia, and North America—enhances the generalizability of these findings, though the authors acknowledge that variations in local HIV management and screening infrastructure may influence real-world outcomes.
Conclusion
This individual patient data meta-analysis provides the most robust evidence to date on the age-specific distribution of cervical precancer in women living with HIV. By establishing that the risk of invasive cancer is low before age 30 and that the risk of high-grade lesions peaks in the late 40s, the study validates the strategic shift toward screening initiation at age 25. Furthermore, the high rates of recurrence post-treatment underscore the necessity of viewing cervical cancer prevention in WLWH as a long-term, chronic management issue rather than a one-time intervention. Expanding access to integrated HIV and cervical cancer screening services is essential to achieving the global goal of eliminating cervical cancer.
Funding and Acknowledgments
This research was supported by the US Agency for International Development (USAID) and the US President’s Emergency Plan for AIDS Relief (PEPFAR). The authors declare no competing interests related to the funding sources.
References
Dalal S, Sundström K, Silva R, Taghavi K, Cejtin H, Chung MH, Greene SA, Joshi S, Kelly H, Manga S, Mayaud P, Orang’o EO, Sohn AH, Herweijer E, Newman Owiredu M, Rangaraj A, Eckert L, Santesso N, Baggaley R, Doherty M, Broutet N. Age-specific distribution of cervical precancer and cancer among women living with HIV across seven countries: a systematic review and an individual patient data meta-analysis. Lancet HIV. 2026 Feb;13(2):e126-e137. doi: 10.1016/S2352-3018(25)00198-5. Epub 2025 Nov 27. PMID: 41319655.
